IQVIA Holdings Inc. (NYSE:IQV) Shares Sold by State of Alaska Department of Revenue

State of Alaska Department of Revenue cut its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 1.6% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 28,887 shares of the medical research company’s stock after selling 465 shares during the quarter. State of Alaska Department of Revenue’s holdings in IQVIA were worth $5,675,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Private Trust Co. NA increased its position in IQVIA by 10.7% in the third quarter. Private Trust Co. NA now owns 485 shares of the medical research company’s stock worth $115,000 after buying an additional 47 shares during the period. Clear Harbor Asset Management LLC grew its position in shares of IQVIA by 1.3% during the third quarter. Clear Harbor Asset Management LLC now owns 3,969 shares of the medical research company’s stock worth $941,000 after acquiring an additional 50 shares during the last quarter. Pine Valley Investments Ltd Liability Co lifted its position in IQVIA by 0.5% in the 3rd quarter. Pine Valley Investments Ltd Liability Co now owns 9,481 shares of the medical research company’s stock valued at $2,247,000 after purchasing an additional 50 shares during the last quarter. Fortitude Family Office LLC boosted its stake in IQVIA by 2.9% during the 3rd quarter. Fortitude Family Office LLC now owns 1,977 shares of the medical research company’s stock valued at $468,000 after purchasing an additional 56 shares during the period. Finally, Huntington National Bank grew its position in IQVIA by 7.4% in the 3rd quarter. Huntington National Bank now owns 809 shares of the medical research company’s stock worth $192,000 after purchasing an additional 56 shares during the last quarter. 89.62% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, Director John G. Danhakl purchased 1,275 shares of the firm’s stock in a transaction that occurred on Tuesday, December 3rd. The stock was acquired at an average cost of $200.58 per share, for a total transaction of $255,739.50. Following the completion of the acquisition, the director now owns 1,275 shares in the company, valued at $255,739.50. This trade represents a ∞ increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 1.60% of the stock is currently owned by corporate insiders.

IQVIA Price Performance

NYSE IQV opened at $208.13 on Friday. IQVIA Holdings Inc. has a 1 year low of $187.62 and a 1 year high of $261.73. The stock’s 50-day moving average price is $200.53 and its two-hundred day moving average price is $219.80. The company has a market cap of $37.78 billion, a PE ratio of 27.31, a PEG ratio of 2.15 and a beta of 1.48. The company has a current ratio of 0.81, a quick ratio of 0.81 and a debt-to-equity ratio of 1.76.

IQVIA (NYSE:IQV) last issued its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a net margin of 9.17% and a return on equity of 28.17%. On average, analysts predict that IQVIA Holdings Inc. will post 10.18 EPS for the current year.

Analysts Set New Price Targets

IQV has been the subject of several analyst reports. JPMorgan Chase & Co. reduced their price objective on IQVIA from $279.00 to $240.00 and set an “overweight” rating for the company in a research report on Tuesday, November 5th. BTIG Research cut IQVIA from a “buy” rating to a “neutral” rating in a research note on Monday, February 3rd. Stifel Nicolaus reduced their price objective on shares of IQVIA from $273.00 to $261.00 and set a “buy” rating for the company in a report on Friday. Barclays lowered their target price on shares of IQVIA from $255.00 to $235.00 and set an “overweight” rating on the stock in a research note on Monday, February 3rd. Finally, Deutsche Bank Aktiengesellschaft reduced their price target on shares of IQVIA from $270.00 to $265.00 and set a “buy” rating for the company in a research note on Friday, November 1st. Five research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, IQVIA has an average rating of “Moderate Buy” and an average target price of $252.39.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.